Daniel Barber - 08 Jun 2022 Form 4 Insider Report for Aquestive Therapeutics, Inc. (AQST)

Reporting relationship: Chief Executive Officer
Issuer ticker: AQST
Reported as of: 08 Jun 2022
Net transaction value: +$100,000
SEC form: 4
Accepted by SEC: 10 Jun 2022, 17:27:06 UTC
Prior SEC filing: 14 Mar 2022
Next SEC filing: 08 Aug 2022
Source filing: View source filing
Reporting owner signature: /s/ Lori J. Braender, as Attorney-in-Fact

Key filing fact

Daniel Barber filed Form 4 for Aquestive Therapeutics, Inc. (AQST) on 10 Jun 2022.

Key facts

This page summarizes Daniel Barber's Form 4 filing for Aquestive Therapeutics, Inc. (AQST).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 10 Jun 2022, 17:27.

Change

Previous filing in this sequence was filed on 14 Mar 2022.
Current net transaction value: +$100,000.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

AQST transaction

Common Stock

Purchase

Transaction value: $88,073
Shares: +91,743
Change %: +90%
Price: $0.9600
Shares after: 193,702
Date: 08 Jun 2022
Ownership: Direct
Footnotes: F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

AQST transaction Derivative

Warrant (Right to Buy)

Purchase

Transaction value: $11,927
Shares: +91,743
Change %
Price: $0.1300^*
Shares after: 91,743
Date: 08 Jun 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 91,743
Exercise price: $0.9600
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Each share of common stock sold to the Reporting Person was sold together with one warrant to purchase one share of common stock at a price per share of $1.09 per share and warrant, of which the price per share of common stock was deemed to be $0.96 and the price per warrant was deemed to be $0.13.